SCHEMBL29831055

SCHEMBL29831055

O=c1cc(O)c2ccc(Br)cc2[nH]1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
ALDH1A1 P00352 2/20 0.59
KDM5A P29375 1/20 0.53
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
HPGD P15428 1/20 0.47
METAP2 P50579 1/20 0.47
GSK3A P49840 3/20 0.44
GSK3B P49841 3/20 0.44
CDK1 P06493 3/20 0.44
CDK5 Q00535 3/20 0.44
CDK5R1 Q15078 3/20 0.44
CCNB2 O95067 2/20 0.44
CCNB1 P14635 2/20 0.44
CCNB3 Q8WWL7 2/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
PIM1 P11309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14796728 1.00 KDM4E (0.59) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL9393238 0.89 KDM4E (0.47) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL2054683 0.85 ALDH1A1 (0.59) KDM4EALDH1A1KDM5AHPGDGSK3A
SCHEMBL29892996 0.79 KDM4E (0.62) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2798886 0.79 KDM4E (0.62) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL9160411 0.78 CHEK1 (0.49) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL8109985 0.78 KDM4E (0.59) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL29171685 0.78 TP53 (0.47) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL8127333 0.78 TP53 (0.66) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL30759515 0.78 TP53 (0.47) KDM4EALDH1A1GAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145599-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MRJA THERAPEUTICS, INC. 2025-05-08 US disclosed
EP-4508061-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) 2025-02-19 EP disclosed
CN-119365479-A Conjugates comprising Toll-like receptor agonists 慕宝盛科生物医药(上海)有限公司 2025-01-24 CN disclosed
CN-118974019-A Certain chemical entities, compositions and methods 瑞图恩制药公司 2024-11-15 CN disclosed
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-06-20 US disclosed
EP-4308564-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
WO-2023198195-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST MABSOFT THERAPEUTICS (SHANGHAI) CO., LTD. (CN) 2023-10-19 WO disclosed
WO-2022197789-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK5 KDM4E 794/4885ALDH1A1 3923/4885KDM5A 508/4885
US-20250145599-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS IGF1R, IGFBP1, IGFBP2 KDM4E 3842/4885ALDH1A1 826/4885KDM5A 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.